Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 2/2017

01-04-2017 | Osteoporosis and Cancer (M Nanes AND M Drake, SECTION EDITORS)

Bone Pain and Muscle Weakness in Cancer Patients

Authors: Daniel P. Milgrom, Neha L. Lad, Leonidas G. Koniaris, Teresa A. Zimmers

Published in: Current Osteoporosis Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems.

Recent Findings

There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass.

Summary

CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.
Literature
1.
2.
3.
4.
Irwin KE, et al. Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis. 2013;10(1):35–47.PubMedCrossRef
5.
Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24(6):425–32.PubMedCrossRef
6.
Lange MB, et al. Diagnostic accuracy of imaging methods for the diagnosis of skeletal malignancies: a retrospective analysis against a pathology-proven reference. Eur J Radiol. 2016;85(1):61–7.PubMedCrossRef
7.
Zhang Y, et al. The added value of SPECT/spiral CT in patients with equivocal bony metastasis from hepatocellular carcinoma. Nuklearmedizin. 2015;54(6):255–61.PubMedCrossRef
8.
Minamimoto R, et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. 2015;56(12):1862–8.PubMedCrossRef
9.
Iagaru A, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14(2):252–9.PubMedCrossRef
10.
11.
Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82(3):166–8.PubMedCrossRef
12.
Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol). 2011;23(6):387–92.CrossRef
13.
14.
Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97(3 Suppl):834–9.PubMedCrossRef
15.
Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev. 2012;32(3):611–36.PubMedCrossRef
16.
Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10(2):169–80.PubMedCrossRef
17.
Guise TA, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 Pt 2):6213s–6s.PubMedCrossRef
18.
Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. 2011;22(5):188–94.PubMedCrossRef
19.
Weidle UH, et al. Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics. 2016;13(1):1–12.PubMed
20.
Wang Y, et al. DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest. 2014;124(4):1646–59.PubMedPubMedCentralCrossRef
21.
Wu W, et al. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. Int J Clin Exp Pathol. 2015;8(10):13217–24.PubMedPubMedCentral
22.
Min Y, et al. C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene. 2011;30(49):4901–9.PubMedPubMedCentralCrossRef
23.
Hiraga T, et al. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007;67(9):4157–63.PubMedCrossRef
24.
Gao YB, et al. Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone. J Cancer Res Clin Oncol. 2013;139(4):669–79.PubMedCrossRef
25.
Mohammad, K.S. and T.A. Guise, Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res. 2003. (415 Suppl): p. S67–74.
26.
Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep. 2006;8(2):108–13.PubMedCrossRef
27.
Hall CL, et al. Role of Wnts in prostate cancer bone metastases. J Cell Biochem. 2006;97(4):661–72.PubMedCrossRef
28.
Mishra, S., et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget. 2015.
29.
30.
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.PubMedCrossRef
31.
32.
Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509–24.PubMedCrossRef
33.
34.
Honore P, Mantyh PW. Bone cancer pain: from mechanism to model to therapy. Pain Med. 2000;1(4):303–9.PubMedCrossRef
35.
Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res. 2000;373:104–14.CrossRef
36.
Gould 3rd HJ, et al. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res. 2000;854(1–2):19–29.PubMedCrossRef
37.
Ji RR, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002;36(1):57–68.PubMedCrossRef
38.
Obata K, et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain. 2002;99(1–2):121–32.PubMedCrossRef
39.
Mantyh WG, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588–98.PubMedPubMedCentralCrossRef
40.
Ghilardi JR, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012;64(7):2223–32.PubMedPubMedCentralCrossRef
41.
42.
Jimenez-Andrade JM, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649–56.PubMedPubMedCentralCrossRef
43.
Schwei MJ, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19(24):10886–97.PubMed
44.
Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain. 1992;48(2):137–46.PubMedCrossRef
45.
Schneider G, Voltz R, Gaertner J. Cancer pain management and bone metastases: an update for the clinician. Breast Care (Basel). 2012;7(2):113–20.CrossRef
46.
Sabino MA, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 2002;62(24):7343–9.PubMed
47.
Gough N, Miah AB, Linch M. Nonsurgical oncological management of cancer pain. Curr Opin Support Palliat Care. 2014;8(2):102–11.PubMedCrossRef
48.
Antman EM, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–42.PubMedCrossRef
49.
King T, et al. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007;132(1–2):154–68.PubMedPubMedCentralCrossRef
50.
Nishihara M, et al. Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician. 2013;16(5):E547–52.PubMed
51.
Pantano F, et al. New targets, new drugs for metastatic bone pain: a new philosophy. Expert Opin Emerg Drugs. 2011;16(3):403–5.PubMedCrossRef
52.
Santini D, et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther. 2006;6(12):1333–48.PubMedCrossRef
53.
Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60(11):2949–54.PubMed
54.
Hiraga T, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004;10(13):4559–67.PubMedCrossRef
55.
Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13(15 Pt 1):4482–6.PubMedCrossRef
56.
Vincenzi B, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interf Cytokine Res. 2005;25(3):144–51.CrossRef
57.
Coleman, R.E. Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer. oncology (Williston Park). 2016. 30(8).
58.
Raje N, et al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J. 2016;6:e378.PubMedPubMedCentralCrossRef
59.
Lipton A, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2015;53:75–83.PubMedCrossRef
60.
Carducci MA, et al. Atrasentan in patients with advanced renal cell carcinoma: a phase 2 trial of the ECOG-ACRIN cancer research group (E6800). Clin Genitourin Cancer. 2015;13(6):531–9. e1 PubMedPubMedCentralCrossRef
61.
Qiao L, et al. Endothelin—a receptor antagonists in prostate cancer treatment—a meta-analysis. Int J Clin Exp Med. 2015;8(3):3465–73.PubMedPubMedCentral
62.
Bougioukli, S., et al. Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone, 2015.
63.
Lee SK, et al. Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio in human osteoblastic cells. J Cancer Prev. 2015;20(4):281–6.PubMedPubMedCentralCrossRef
64.
Rucci N, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318(1):161–72.PubMedCrossRef
65.
• Brown DC, Agnello K, Iadarola MJ. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. Pain. 2015;156(6):1018–24. This paper proposes a promising novel therapy for CIBP PubMedPubMedCentral
66.
Cojoc M, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6:1347–61.PubMedPubMedCentral
67.
Lutz S. The role of radiation therapy in controlling painful bone metastases. Curr Pain Headache Rep. 2012;16(4):300–6.PubMedCrossRef
68.
Dennis K, et al. Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials. Radiother Oncol. 2013;106(1):5–14.PubMedCrossRef
69.
McDonald R, et al. Quality of life after palliative radiotherapy in bone metastases: a literature review. J Bone Oncol. 2015;4(1):24–31.PubMedCrossRef
70.
Wolanczyk MJ, Fakhrian K, Adamietz IA. Radiotherapy, bisphosphonates and surgical stabilization of complete or impending pathologic fractures in patients with metastatic bone disease. J Cancer. 2016;7(1):121–4.PubMedPubMedCentralCrossRef
71.
Chow E, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(15):1463–72.PubMedCrossRef
72.
Yu HH, Hoffe SE. Beyond the conventional role of external-beam radiation therapy for skeletal metastases: new technologies and stereotactic directions. Cancer Control. 2012;19(2):129–36.PubMed
73.
Kothari G, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54(2):148–57.PubMedCrossRef
74.
Kim H, et al. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Int J Radiat Oncol Biol Phys. 2015;91(3):556–63.PubMedCrossRef
75.
Wong E, et al. Re-irradiation for painful bone metastases—a systematic review. Radiother Oncol. 2014;110(1):61–70.PubMedCrossRef
76.
Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012;19(2):137–44.PubMed
77.
Napoli A, et al. MR imaging-guided focused ultrasound for treatment of bone metastasis. Radiographics. 2013;33(6):1555–68.PubMedCrossRef
78.
79.
Quinn RH, et al. Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners. J Bone Joint Surg Am. 2013;95(20):1887–95.PubMed
80.
Wood TJ, et al. Surgical management of bone metastases: quality of evidence and systematic review. Ann Surg Oncol. 2014;21(13):4081–9.PubMedCrossRef
81.
82.
Rao PJ, et al. Minimally invasive percutaneous fixation techniques for metastatic spinal disease. Orthop Surg. 2014;6(3):187–95.PubMedCrossRef
83.
Smith HS. Painful boney metastases. Ann Palliat Med. 2012;1(1):14–31.PubMed
84.
85.
Dodson S, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265–79.PubMedCrossRef
86.
Sjoblom, B., et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016.
87.
88.
Ryan AM, et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75(2):199–211.PubMedCrossRef
89.
Marino FE, Risbridger G, Gold E. Activin-betaC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle. 2015;6(4):365–80.PubMedPubMedCentralCrossRef
90.
Han HQ, et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45(10):2333–47.PubMedCrossRef
91.
Laurent, M.R., et al. Muscle-bone interactions: From experimental models to the clinic? A critical update. Mol Cell Endocrinol. 2015.
92.
93.
Sala D, Sacco A. Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr Opin Clin Nutr Metab Care. 2016;19(3):171–6.PubMedPubMedCentral
94.
Zimmers, T.A., M.L. Fishel, and A. Bonetto. STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol, 2016.
95.
Rom, O. and A.Z. Reznick. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med, 2015.
96.
Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006;26:435–61.PubMedCrossRef
97.
Argiles JM, et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005;37(5):1084–104.PubMedCrossRef
98.
Toth MJ, et al. Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. J Appl Physiol (1985). 2013;114(7):858–68.CrossRef
99.
Gilliam LA, Clair DKS. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15(9):2543–63.PubMedPubMedCentralCrossRef
100.
Kumar NB, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options in Oncol. 2010;11(3–4):107–17.CrossRef
101.
Argiles JM, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–6.PubMedCrossRef
102.
Wen HS, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy. 2012;58(6):461–7.PubMedCrossRef
103.
Dobs AS, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45.PubMedPubMedCentralCrossRef
104.
• Temel, J.S., et al., Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 2016. This paper gives the results of two phase 3 trials, in which anamorelin had success in restoring lean muscle mass in patients with cachexia.
105.
Busquets S, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle. 2012;3(1):37–43.PubMedCrossRef
106.
Ebner N, et al. Highlights from the 7th cachexia conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014;5(1):27–34.PubMedPubMedCentralCrossRef
107.
Toledo M, et al. Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and beta-2 agonist. Int J Cancer. 2016;138(8):2021–9.PubMedCrossRef
108.
Bellinger AM, et al. Remodeling of ryanodine receptor complex causes “leaky” channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A. 2008;105(6):2198–202.PubMedPubMedCentralCrossRef
109.
Smith RC, et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther. 2015;14(7):1661–70.PubMedCrossRef
110.
111.
112.
Bonetto A, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410–21.PubMedPubMedCentralCrossRef
113.
114.
Ohuchi H, Noji S. Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Cell Tissue Res. 1999;296(1):45–56.PubMedCrossRef
115.
116.
Hamrick MW, et al. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res. 2006;21(3):477–83.PubMedCrossRef
117.
Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10(1):56–63.PubMedPubMedCentral
118.
119.
120.
Lee SJ, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102(50):18117–22.PubMedPubMedCentralCrossRef
121.
Chen JL, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28(4):1711–23.PubMedCrossRef
122.
Zhou X, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531–43.PubMedCrossRef
123.
Bowser M, et al. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol. 2013;48(2):290–7.PubMedCrossRef
124.
Korpal M, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960–6.PubMedCrossRef
125.
Hubackova S, et al. IL1- and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. Aging (Albany NY). 2012;4(12):932–51.CrossRef
126.
Schiaffino S, et al. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280(17):4294–314.PubMedCrossRef
127.
Kagiya T. MicroRNAs and osteolytic bone metastasis: the roles of MicroRNAs in tumor-induced osteoclast differentiation. J Clin Med. 2015;4(9):1741–52.PubMedPubMedCentralCrossRef
128.
Burne TH, et al. Swimming behaviour and post-swimming activity in vitamin D receptor knockout mice. Brain Res Bull. 2006;69(1):74–8.PubMedCrossRef
129.
Mongre RK, et al. A new paradigm to mitigate osteosarcoma by regulation of microRNAs and suppression of the NF-kappaB signaling Cascade. Dev Reprod. 2014;18(4):197–212.PubMedPubMedCentralCrossRef
130.
Ell B, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24(4):542–56.PubMedCrossRef
131.
Pollari S, et al. Identification of microRNAs inhibiting TGF-beta-induced IL-11 production in bone metastatic breast cancer cells. PLoS One. 2012;7(5):e37361.PubMedPubMedCentralCrossRef
Metadata
Title
Bone Pain and Muscle Weakness in Cancer Patients
Authors
Daniel P. Milgrom
Neha L. Lad
Leonidas G. Koniaris
Teresa A. Zimmers
Publication date
01-04-2017
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 2/2017
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-017-0354-3

Other articles of this Issue 2/2017

Current Osteoporosis Reports 2/2017 Go to the issue

Therapeutics and Medical Management (S Jan de Beur and B Clarke, Section Editors)

Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy

Skeletal Development (P Trainor and K Svoboda, Section Editors)

Functional Diversity of Ciliary Proteins in Bone Development and Disease

Rare Bone Disease (C Langman and E Shore, Section Editors)

Current Care and Investigational Therapies in Achondroplasia

Therapeutics and Medical Management (S Jan de Beur and B Clarke, Section Editors)

Osteoporosis: Treat-to-Target

Rare Bone Disease (C Langman and E Shore, Section Editors)

Microcephalic Osteodysplastic Primordial Dwarfism, Type II: a Clinical Review

Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis